Portola Pharmaceuticals Overview
- Year Founded
-
2003
- Status
-
Acquired/Merged
- Employees
-
408
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.62B
Portola Pharmaceuticals General Information
Description
Portola Pharmaceuticals Inc is a biotechnology company focused on developing and commercializing novel therapeutics. The company focuses on areas of thrombosis, other hematologic disorders, and inflammation for patients who have limited or no approved treatment options. Portola focuses on biomarker or genetic approaches to clinical development that it believes will increase the probability of clinical, regulatory, and commercial success of first-in-class therapies. The company also uses collaborative agreements.
Contact Information
Website
www.portola.comCorporate Office
- 270 East Grand Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 270 East Grand Avenue
- South San Francisco, CA 94080
- United States
Portola Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 15. Merger/Acquisition | 02-Jul-2020 | $1.62B | Completed | Generating Revenue | ||
| 14. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 13. Secondary Transaction - Open Market | 30-Jun-2018 | Completed | Generating Revenue | |||
| 12. PIPE | 03-Feb-2017 | Completed | Generating Revenue | |||
| 11. PIPE | 25-Jan-2016 | Completed | Generating Revenue | |||
| 10. Secondary Transaction - Stock Distribution | 18-Feb-2014 | Completed | Generating Revenue | |||
| 9. 2PO | 17-Oct-2013 | Completed | Generating Revenue | |||
| 8. IPO | 22-May-2013 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series 1) | 14-Dec-2011 | $9M | $338M | Completed | Generating Revenue | |
| 6. Later Stage VC (Series D) | 21-Nov-2011 | $89M | $329M | Completed | Generating Revenue |
Portola Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series 1 | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 36,750,400 | $0.001000 | 8% | $1.31 | $1.31 | 1x | $1.31 | 12.38% |
| Series A | 43,147,400 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 14.54% |
Portola Pharmaceuticals Comparisons
Industry
Financing
Details
Portola Pharmaceuticals Competitors (58)
One of Portola Pharmaceuticals’s 58 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Northwest Biotherapeutics | Corporation | Bethesda, MD | ||||
| Alaunos Therapeutics | Formerly VC-backed | Fort Lauderdale, FL | ||||
| Intas Pharmaceuticals | Private Equity-Backed | Ahmedabad, India | ||||
| Genzyme Ireland | Corporation | Kilmeaden, Ireland |
Portola Pharmaceuticals Signals
Portola Pharmaceuticals Former Investors (37)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abingworth | Venture Capital | Minority | ||
| Adage Capital Management | Hedge Fund | Minority | ||
| Advanced Technology Ventures | Venture Capital | Minority | ||
| AllianceBernstein | Asset Manager | Minority | ||
| Alta Partners | Venture Capital | Minority |
Portola Pharmaceuticals Investments (2)
Portola Pharmaceuticals’s most recent deal was a Seed Round with PayPool for . The deal was made on 02-Sep-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| PayPool | 02-Sep-2022 | Seed Round | Other Financial Services | ||
| Arete Therapeutics | 10-May-2007 | Early Stage VC | Drug Discovery |
Portola Pharmaceuticals ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Portola Pharmaceuticals FAQs
-
When was Portola Pharmaceuticals founded?
Portola Pharmaceuticals was founded in 2003.
-
Where is Portola Pharmaceuticals headquartered?
Portola Pharmaceuticals is headquartered in South San Francisco, CA.
-
What is the size of Portola Pharmaceuticals?
Portola Pharmaceuticals has 408 total employees.
-
What industry is Portola Pharmaceuticals in?
Portola Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Portola Pharmaceuticals a private or public company?
Portola Pharmaceuticals is a Private company.
-
What is the current valuation of Portola Pharmaceuticals?
The current valuation of Portola Pharmaceuticals is .
-
What is Portola Pharmaceuticals’s current revenue?
The current revenue for Portola Pharmaceuticals is .
-
How much funding has Portola Pharmaceuticals raised over time?
Portola Pharmaceuticals has raised $616M.
-
Who are Portola Pharmaceuticals’s investors?
Abingworth, Adage Capital Management, Advanced Technology Ventures, AllianceBernstein, and Alta Partners are 5 of 37 investors who have invested in Portola Pharmaceuticals.
-
Who are Portola Pharmaceuticals’s competitors?
Dicerna Pharmaceuticals, Northwest Biotherapeutics, Alaunos Therapeutics, Intas Pharmaceuticals, and Genzyme Ireland are some of the 58 competitors of Portola Pharmaceuticals.
-
When was Portola Pharmaceuticals acquired?
Portola Pharmaceuticals was acquired on 02-Jul-2020.
-
Who acquired Portola Pharmaceuticals?
Portola Pharmaceuticals was acquired by Alexion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process